Topotecan and Melphalan for Retinoblastoma
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
Retinoblastoma|Chemotherapy Effect
DRUG: Topotecan|DRUG: Melphalan
Eyeball-sparing rate, Eyeball-sparing rate during chemotherapy in retinoblastoma patients, 5 years after chemotherapy
Side effects, Side effects during and after chemotherapy in retinoblastoma patients, 5 years after chemotherapy
To evaluate the effectiveness and complications of topotecan and melphalan for intraocular injection in retinoblastoma patients.